Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, February 1998, p. 319-324, Vol. 42, No. 2
Department of Medical Microbiology,
Received 3 March 1997/Returned for modification 19 July
1997/Accepted 26 November 1997
We analyzed the antimicrobial susceptibilities of Haemophilus
influenzae isolates from 157 sputum specimens prospectively collected from 39 cystic fibrosis (CF) patients during a 2-year study.
These isolates were characterized by random amplified polymorphic DNA analysis and major outer membrane protein (MOMP) analysis to
identify H. influenzae strains and MOMP variants and
to assess their persistence in the respiratory tract. Among the 247 H. influenzae isolates, 16 (6.5%) produced
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Antimicrobial Susceptibility of Haemophilus
influenzae in the Respiratory Tracts of Patients with Cystic
Fibrosis
-lactamase. The 231
-lactamase-negative isolates represented 85 H. influenzae strains, 61 MOMP variants derived from
27 of these strains, and 85 persistent isolates identical to strains or
MOMP variants. All
-lactamase-negative isolates were tested for
susceptibility to ampicillin, amoxicillin-clavulanic acid, cefuroxime,
cefotaxime, cefaclor, imipenem, tetracycline, and
trimethoprim-sulfamethoxazole by disk diffusion testing. Eleven (13%)
H. influenzae strains, 18 (30%) MOMP variants, and 30 (35%) persistent isolates were resistant to one or more of the
antibiotics tested. Antimicrobial susceptibility was decreased among
MOMP variants and persistent isolates compared to nonpersistent
H. influenzae strains, and changes in susceptibility
occurred irrespective of MOMP variation. We conclude that the decreased
antimicrobial susceptibility of H. influenzae during
persistence contributes to the poor eradication of H. influenzae from the respiratory tracts of CF patients.
*
Corresponding author. Mailing address: Laboratory for
Vaccine Development and Mechanisms of Immunity (L.V.M.), National
Institute for Public Health and Environment (RIVM), P.O. Box 1, NL-3720 BA Bilthoven, The Netherlands. Phone: 31-30-2742701. Fax:
31-30-2744429. E-mail: Loek.van.Alphen{at}RIVM.NL.
Antimicrobial Agents and Chemotherapy, February 1998, p. 319-324, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»